Wall Street brokerages forecast that Xencor, Inc. (NASDAQ:XNCR) will post $8.15 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Xencor’s earnings, with estimates ranging from $6.00 million to $10.30 million. Xencor reported sales of $7.82 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4.2%. The company is expected to issue its next earnings report on Wednesday, November 1st.

On average, analysts expect that Xencor will report full-year sales of $8.15 million for the current financial year, with estimates ranging from $25.10 million to $38.30 million. For the next year, analysts expect that the firm will report sales of $28.10 million per share, with estimates ranging from $20.00 million to $36.20 million. Zacks’ sales averages are an average based on a survey of research firms that follow Xencor.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The business had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%.

Several research firms have recently weighed in on XNCR. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Canaccord Genuity restated a “buy” rating and issued a $36.00 target price on shares of Xencor in a research report on Tuesday, August 8th. Wedbush restated an “outperform” rating and issued a $29.00 target price on shares of Xencor in a research report on Friday, June 16th. ValuEngine upgraded Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $29.33.

Shares of Xencor (XNCR) traded down 1.02% during mid-day trading on Friday, hitting $22.26. The stock had a trading volume of 207,431 shares. Xencor has a one year low of $18.45 and a one year high of $29.38. The stock’s market cap is $1.04 billion. The firm has a 50 day moving average of $21.54 and a 200-day moving average of $22.56.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Xencor, Inc. (XNCR) Will Announce Quarterly Sales of $8.15 Million” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/20/zacks-brokerages-anticipate-xencor-inc-xncr-will-announce-quarterly-sales-of-8-15-million.html.

In related news, major shareholder John S. Stafford III acquired 27,000 shares of Xencor stock in a transaction that occurred on Friday, August 11th. The shares were purchased at an average price of $21.13 per share, for a total transaction of $570,510.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder John S. Stafford III acquired 25,000 shares of Xencor stock in a transaction that occurred on Wednesday, August 16th. The shares were bought at an average price of $20.96 per share, for a total transaction of $524,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 221,551 shares of company stock worth $4,506,556. 4.14% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Equitec Specialists LLC purchased a new position in Xencor during the second quarter worth approximately $116,000. SG Americas Securities LLC lifted its position in Xencor by 62.6% during the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,252 shares in the last quarter. Airain ltd purchased a new position in Xencor during the first quarter worth approximately $213,000. Legal & General Group Plc lifted its position in Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Xencor during the second quarter worth approximately $224,000. Hedge funds and other institutional investors own 76.92% of the company’s stock.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.